DAFTAR PUSTAKA

1.

Botham KM, Mayes PA. Pengangkutan dan penyimpanan lipid. In:

Wulandari N, Rendy L, Dwijayanthi L, Liena, Dany L, Rachman LY,ed.
Biokimia Harper. 27th ed. Jakarta: EGC; 2006:225-249.

2.

Zannis VI, Kypreos KE, Dimitris AC. Lipoproteins and atherogenesis. In:
Loscalzo J,ed. Molecular Mechanisms of Atherosclerosis. USA: Taylor &
Francis; 2005: 154-244.

3.

Waldius G, Jungner I. The Apo B / Apo A-1 ratio: a strong, new risk
factor for cardiovascular disease and a target for lipid-lowering therapy.
A review of the evidence. Jour Of Int Med.2006; 259: 493-519

4.

Mc Queen MJ. Hawken S, Wang X. INTERHEART study investigator et

al. lipids, lipoprotein, and apolipoprotein as risk marker of myocardial
infarction in 52 countries (The INTERHEART Study) ; A Case Control
Study. Lancet.2008; 372: 224-233.

5.

Holme I, Aastveit AH, Jungner I, Waldius G. Relationships between

lipoprotein components and risk of myocardial infarction: age, gender
and short versus longer follow-up periods in the Apolipoprotein MOrtality
RISk study (AMORIS)

6.

Riediger ND, Bruce SG, Young TK. Cardiovascular risk according to

plasma apolipoprotein and lipid profiles in a Canadian First Nation. Prev
Chronic.Dis.2011;8(1):http://www.cdc.gov/pcd/issues/2011/jan/09_0216.
htm. Accessed Desember 20, 2011.

Universitas Sumatera Utara

7.

Kibak P. Predicting heart attack risk, more evidence suggests

apolipoprotein ratio beter than cholesterol ratio, clinical laboratory
strategiest. Lancet 2008; 372: 224-33.

8.

Yusuf S, Hawken S, unpuu S, et al. Effect potentially modifiable risk

factors associated with myocardial infarction in 52 Countries ( The
INTERHEART Study) : Case- Control Study. Lancet. 2004; 364: 937-52.

9.

Kulkarni K, Tiwari H, Moore L, Jones S. A novel approach to measure

apolipoprotein B / apolipoprotein A-1 ratio using the vertical auto profil
method. Diabetes Vasc Dis Res. 2007; 4: 266.

10. Sachu P, Philips A, Sheriff DS. Apo B/ Apo A-1 ratio a better predictor of
coronary artery disease in patient with or without type II diabetes
mellitus. International Journal Of Applied Biologis and Pharmaceutical
Technology. 2011; 2: 153.
11. Mc Phee SJ, Papadakis MA, Rabow MW. Prevention of overweight and
obesity. In: Lange Current Medical Diagnosis & Treatment. California:
Mc Graw Hill; 2011: 14-15.
12. Toth P, Sica DA, Clinical Challenges in Lipid Disorders. Oxford: Atlas
Medical Publishing; 2008: 1-283.
13. Colledge NR, Walker BR, Ralston SH. Davidsons Principles & Practice
of Medicine: Elsevier; 2010: 803-804.
14. Grundi SM, Cleeman JI, Daniels SR. et al. Diagnosis and management
of the metabolik syndrome an American Heart Association/National
Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;
112: 2735-2752.

Universitas Sumatera Utara

15. Renaldi O. Peran adiponektin terhadap kejadian resistensi insulin pada

sindrom metabolik. Medicinus. 2009; 22: 65-70
16. Zimmet P, Alberti KGMM, Kaufman F,et al. International Diabetes
Federation (IDF). The IDF Consensus Worldwide Definition Of The
Metabolic Syndrome. 2006: 1-23
17. Sormin IP, Lukito W, Wijaya A, Asad S. Negative impact of inflamation
and insulin resistance on the biogenesis of HDL-C in Indonesian men
with metabolic syndrome. Med J Indones. 2010; 19: 36-45
18. Pranoto A, Kholili U, Tjokroprawiro A, Sutjahjo A, Murtiwi S, Soebagijo
AS. Metabolic syndrome as observed in Surabaya. Universitas Airlangga
19. Sargowo D, Andarini S. Pengaruh komposisi asupan makanan terhadap
komponen sindrom metabolik pada remaja. J Kardiol Indones. 2011; 32:
14-23.
20. Background
Perencanaan

Study

RPJMN

Pembangunan

2010-2014.
Nasional.

Kementrian
Badan

Negara

Perencanaan

Pembangunan Nasional ; 2009.

21. Pusparini. Obesitas sentral, sindroma metabolik dan diabetes melitus
tipe dua. Universa Medicina. 2007; 26: 195-264.
22. Soegondo S. Prinsip pengobatan diabetes, Obat hipoglikemik oral dan
insulin. Dalam: Soegondo S, Soewondo P dan Subekti I, ed. Diabetes
Melitus : Penelitian Terpadu. Jakarta: Balai Penerbit FKUI
23. Soegondo S. Atherogenic dyslipidemia and the metabolic syndrome
clinical practice. Acta Med Indones-Indones J Intern Med 2005; 37:177183.

Universitas Sumatera Utara

24. Wallenfeldt K, Bokemark L, Wikstrand J, et al. Apolipoprotein

B/apolipoprotein A-1 in relation to the metabolic syndrome and change in
carotid artery intima-media thickness during 3 years in middle-aged men.
Stroke. 2004; 35: 000-000.
25. Lind L, Vessby B, Sundstrm J. The apolipoprotein B/A1 ratio and the
metabolic syndrome independently predict risk for myocardial infarction
in middle-aged men. Arterioscler Thromb Vasc Biol. 2006; 26: 406-410.
26. Lamarche B, Moorjani S, Lupien PJ,et al. Apolipoprotein A-I and B levels
and the risk of ischemic heart disease during a five-year follow-up of
men in the quebec cardiovascular study. Circulation. 1996; 94: 273-278
27. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of
apolipoprotein B and A-I in the prediction of myocardial infarction in
middle-aged men and women: results from the MONICA/KORA
Augsburg cohort study. European Heart Journal. 2005; 26: 271-278
28. Mattsson N, Magnussen CG, Rnnemaa T, Mallat Z, Benessiano J, Jula
A. et al. Metabolic syndrome and carotid intima-media thickness in
young adults: roles of apolipoprotein B, apolipoprotein A-I, C-Reactive
Protein, and secretory phospholipase A2: The cardiovascular risk in
young finns study. Arterioscler Thromb Vasc Biol 2010; 30:1861-1866.
29. Pownall HJ, Gotto AM, Human Plasma Lipoprotein Metabolism. In:
Ballantyne CM. ed. Clinical Lipidology: A Companion To Braunwalds
Heart Disease. Philadelphia: Saunders Elsevier; 2009: 1-10

Universitas Sumatera Utara

30. Mahley RW. Biochemistry and physiology of lipid and lipoprotein

metabolism. In: Becker. ed. Principles and Practice Of Endocrinology
and Metabolism. Lippincott Co; 1995: 1369-1401.
31. Executive summary of the third report of the National Cholesterol
Education Program (NCEP) expert panel on detection, evaluation, and
treatment of high blood cholesterol in adults (adult treatment panel III).
JAMA. 2001; 285: 248697.
32. Moffatt RJ, Stamford B. Lipid Metabolism and Health. USA: Taylor &
Francis Group; 2006: 147-163.
33. Walldius G , Jungner I. The apoB/apoA-I ratio: a strong, new risk factor
for cardiovascular disease and a target for lipid-lowering therapy a
review of the evidence. Intern Med. 2006; 259: 493519.
34. Barter PJ, et al. Apo B versus cholesterol in estimating cardiovascular
risk and in guiding therapy: report of the thirty-person / ten-country
panel. J Intern Med. 2006; 259: 247-258.
35. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein
AI and apolipoprotein B plasma levels. J Intern Med. 2006; 259: 437-46.
36. Manual Cobas Integra. Roche Indonesia
37. Rader DJ, Hobbs HH. Disorders of lipoprotein metabolism. In : Kasper
DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, ed.
Harrisons Endocrinology. 2nd ed. New York, NY: McGraw-Hill; 2010:
323-346
38. Marcovina S, Packard CJ. Measurement and meaning of apolipoprotein
AI and apolipoprotein B plasma levels. J Intern Med. 2006; 259: 437-46.

Universitas Sumatera Utara

39. Waldius G, Aastveit AH, Jungner I. Stroke mortality and the apoB/apoAI ratio: results of the AMORIS prospective study. J Intern Med. 2006;
259: 259-66
40. Thompson A, Danesh J. Association between apolipoprotein B,
apolipoprotein

AI , the apolipoprotein B/AI ratio and coronary heart

disease: a literature-based meta-analysis of prospective studies. J Intern

Med. 2006; 259: 481-492.
41. Yusuf S, Mente A, Islam S, et al. Metabolic syndrome and risk of acute
myocardial infarction. a case-control study of 26.903 subjects from 52
countries. Journal of the American College of Cardiology.2010; 55:
2390-98
42. Rifai N, Warnick GR. Lipids, lipoproteins, apolipoproteins, and other
cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE. ed.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4ed.
India: Elsevier; 2006: 958-959.
43. Immunoturbidimetry vs Nephelometry, Randox Indonesia
44. Marmer DJ, Hurtubise PE. NepheIometric and immunturbidimetric. In:
Diamandis

EP, Christopoulos

TK, ed. Immunoassay. Academic

press.California; 1996: 371-385

45. McPhee SJ, Ganong WF. Patofisiologi Penyakit. Pengantar

Menuju

Kedokteran Klinis 5th ed. Jakarta: EGC; 2007.

46. Silbernagl S, Lang F. Alih Bahasa Setiawan I, Mochtar I. Teks & Atlas
Berwarna Patofisiologi. Jakarta : EGC. 2006.

Universitas Sumatera Utara

47. Eckel RH, Grundy SM, Zimmet P. The metabolic syndrome. Lancet.
2005;365: 1415-28
48. Inoue S, Zimmet P, et al. The Asia-Pacific Perspective: Redefining
Obesity

and Its Treatment.WHO Western Asia-Pasific Perspective.

Australia; 2000.
49. Mittal S. The Metabolic Syndrome in Clinical Practice. Springer-Verlag;
2008.
50. Byrne CD, Wild SH. The Metabolic Syndrome. England: John Wiley &
Sons; 2005
51. Kaplan

NM.

The

deadly

quarted.

upperbody

obesity,

glucose

intolerance, hypertrigliseridemia, and hypertension. Arch Intern Med.

1989; 149: 1514-20
52. Alberti KGMM, Zimmet PZ. For the WHO consultation, definition,
diagnosis and classification of diabetes mellitus and its complication:
Part 1. Diagnosis and classification of diabetes mellitus provision report
of a WHO consultation. Diabet Med.1998;15: 539-53.
53. Eckel RH, The metabolic syndrome . In : Kasper DL, Fauci AS, Longo
DL,

Braunwald

E,

Hauser

SL,

Jameson

JL,

ed.

Harrisons

Endocrinology. 2nd ed. New York, NY: McGraw-Hill; 2010 :259

54. Leslie, B. Metabolic syndrome: Historical perspectives. The American
Journal of the Medical Sciences. 2005; 330(6) : 264-268.

Universitas Sumatera Utara

55. Reaven G.M., Insulin resistance and its consequences: Non-insulindependent diabetes mellitus and Coronary heart disease. In: LeRoith D.,
Taylor S.I., and Olefsky J.M., ed. Diabetes Mellitus: A Fundamental and
Clinical Text. Lippincott-Raven;1996: 509-519.
56. Krentz,AJ, Wong ND. Metabolic Syndrome and Cardiovascular Disease,
Epidemiology, Assessment, and Management, New York,NY
57. Soegondo S. Obesitas pada sindroma metabolik : penyebab atau akibat.
In: Setiati S, Alwi I, Simadibrata M, Sari NK, Chen K ed. Naskah
Lengkap Pertemuan Ilmiah Tahunan (PIT) Ilmu Penyakit Dalam 2005.
Jakarta: Departemen Penyakit Dalam UI. 2005: 83-86
58. Petrucelli

OM.

The

metabolic

syndrome.

Northeast

Florida

Medicine.2008; 59: 18-21.

59. Davies TF, et al. A Case-Based Guide to Clinical Endocrinology.
Humana Press, 2008
60. Aquilante CL, Griend JP. Metabolic syndrome pharmacotherapy selfassessment program. 2008; 6: 109-128.
61. Petit W, Adamec C. The Encyclopedia of Endocrine Diseases and
Disorders. New York: Facts on file, Inc; 2005: 145-148.
62. Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, et al.
Harrisons Principles of Internal Medicine 17th ed. USA: McGraw-Hill;
2008.
63. Krentz,AJ. Insulin Resistance a Clinical Handbook. Germany: Blackwell
Science Ltd ;2002: 1-9

Universitas Sumatera Utara

64. Zimmet P, Alberti KGMM, Kaufman F,et al. IDF Consensus Group. The
Metabolic Syndrome in Children and Adolescents an IDF Consensus
Report; 2007
65. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic
syndrome among U.S. adults. Diabetes Care. 2004; 27(10): 2444-2449.
66. McTernan P, Kumar S. Pathogenesis of obesity-related type 2 diabetes.
In: Barnett AH, Kumar S.ed. Obesity & Diabetes. USA: John Wiley &
Sons; 2004: 49-78
67. Thompson G, Morrell J, Wilson P. Dyslipidaemia in clinical practice.2nd
ed. UK: Informa Healthcare; 2006. p21-29.
68. Sastroasmoro S, Ismael S. Dasar-dasar Metode Penelitian Klinis 3th ed
Jakarta: Sagung Seto; 2008.
69. Balai Penelitian dan Pengembangan Kesehatan , Depkes RI. Pedoman
Pengukuran dan Pemeriksaan. Riset Kesehatan Dasar 2007
70. Syukran OKA, Mardianto, Lindarto D, Bahri C, Piliang S. Sindroma
metabolik pada karyawan/staf perkebunan. Dalam : Tjokroprawiro A,
Hendromartono, Sutjahjo A, dkk (editors). The Metabolic Syndrome (The
MetS). Anticipating Life Style Related Diseases. Jakarta.2005;105-11
71. Sibarani RP, Rudijanto A, Dekker J, Hiene RJ. The petai china study:
metabolic syndrome among obese Indonesian chinese adolescent. The
Indonesian Journal of Internal Medicine.2006; 38:142-144.
72. Chaniago LS. Penyakit Arteri Perifer Pada Sindroma Metabolik.Disertasi
di Bagian/SMF Penyakit Dalam FK-USU/RSUP H Adam Malik Medan.
2007.USU e-Repository

Universitas Sumatera Utara

73. Rahman S. Perbandingan Kadar Adiponectin Pada Penderita Sindroma

Metabolik dengan Penderita DM Tipe 2 Baru. Disertasi di Bagian/SMF
Penyakit Dalam FK-USU/RSUP H Adam Malik Medan. 2007.USU eRepository
74. Sawant A, Mankeshwar R, Raghavan R.et al. Prevalence of metabolic
syndrome in urban india. Cholesterol. 2011; 1-7.
75. Richard EB, Robert MK,Hal BJ. Defect in metabolism of lipids. In: Nelson
Textbook of Pediatrics. 17th ed.Philadelphia,Pennsylvania.2004;448
76. Sattar N, Ken W, Allan DS, Ralph DA, Steven M. Comparison of the
associations of apolipoprotein B and non-high-density lipoprotein
cholesterol with other cardiovascular risk factors in patiens with the
metabolic syndrome in the insulin resistance atherosclerosis study.
Circulation 2004;110: 2687-2693

Universitas Sumatera Utara